BrandWikiReturn

CanSino Biologics

CanSino Biologics, often abbreviated as CanSinoBIO, is a Chinese vaccine company.[1]

History

CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.[1]

In July 2018, it filed an application to list on the Hong Kong Stock Exchange.[1] It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017.[2] In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR market where it raised 5.2 billion yuan (US$750 million).[3]

Vaccines

The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19.[1][4] The company has previously collaborated with the National Research Council of Canada (NRC) on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.[5][6][7]

COVID-19 vaccine development

AD5-nCOV, trade-named Convidecia, is a single-dose[8] viral vector COVID-19 vaccine developed by CanSino. Since late 2020, it has been in Phase III trials in Chile,[9] Mexico,[10] Pakistan,[11] Russia,[12] and Saudi Arabia[11] with 40,000 participants.

In February 2021, global data from Phase III trials and 101 COVID cases showed that the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease.[13] It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial.[14][8] Its single-dose regimen and normal refrigerator storage requirement make it a favorable vaccine option for many countries.[14] The vaccine is approved for emergency use listing by the WHO.[15]

In April 2021, CanSino Biologics began clinical trials for a version of its COVID-19 vaccine administered by inhalation rather than injection.[16] Rollout of inhaled boosters began in China in October 2022.[17]

Convidecia is approved for use by some countries in Asia,[18][19][20] Latin America,[21][22][23] and by Hungary.[24][25] Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China,[26] Malaysia,[20] Mexico,[27] and Pakistan.[28]

Investors

As of 2018, CanSino Biologics investors included Lilly Asia Ventures, Qiming Venture Partners and SDIC Fund Management.[1]

See also

  • Sinovac
  • Sinopharm

References

  1. Eric Ng. Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal South China Morning Post, 25 July 2018, retrieved 18 April 2020^
  2. Zoe Low. Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China's domestic market South China Morning Post, 29 March 2019, retrieved 18 April 2020^
  3. Daniel Ren. Covid-19 vaccine maker CanSino soars in Star Market debut South China Morning Post, 13 August 2020, retrieved 15 August 2020^
  4. Zhuang Pinghui. Volunteers needed for second phase of China coronavirus vaccine trial South China Morning Post, 10 April 2020, retrieved 18 April 2020^
  5. National Research Council Canada. The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19 Newswire, retrieved 19 May 2020^
  6. National Research Council contribution plays key role in newly approved Ebola vaccine National Research Council Canada, March 20, 2018, retrieved 6 February 2021^
  7. Canada's surprising history and questionable partnership with a Chinese company and its military-backed COVID-19 vaccine nationalpost, retrieved 2021-05-21^
  8. It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective Fortune, retrieved 2021-02-11^
  9. Gob.cl - Article: Science Minister: "We Work With Maximum Rigor So That Science And Technology Benefit People'S Health" Government of Chile, retrieved 2020-11-21^
  10. Chinese Covid vaccine trials to be expanded to five more states Mexico News Daily, 2020-11-10, retrieved 2020-11-11^
  11. Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above - Full Text View - ClinicalTrials.gov clinicaltrials.gov, retrieved 2020-10-21^
  12. Russia approves clinical trials for Chinese COVID-19 vaccine Ad5-Ncov: Ifax Reuters, 2020-12-07, retrieved 2020-12-07^
  13. CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says Reuters, 8 February 2021, retrieved 2021-02-08^
  14. China's CanSino Covid Vaccine Shows 65.7% Efficacy Bloomberg.com, 2021-02-08, retrieved 2021-02-10^
  15. COVID-19 Vaccines with WHO Emergency Use Listing WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control), WHO, 3 November 2021, retrieved 10 April 2023^
  16. CanSino Biologics to start clinical trials of inhaled Covid-19 vaccine Pharmaceutical Technology, 2021-04-20, retrieved 2022-02-15^
  17. Jiaxuan Gao. Vaccination with CanSinoBIO's inhaled COVID-19 vaccine has begun in China Journal of Biosafety and Biosecurity, December 2022^
  18. Roxanne Liu. China approves two more domestic COVID-19 vaccines for public use Reuters, 2021-02-25, retrieved 2021-02-26^
  19. Pakistan purchases over 30 million COVID doses from China: sources ARY NEWS, 2021-04-25, retrieved 2021-04-26^
  20. Malaysia to receive CanSino vaccine this month The Malaysian Insight, 2021-04-01, retrieved 2021-04-03^
  21. 'Our gratitude always': From China's CanSino, Mexico welcomes biggest vaccine shipment yet Reuters, 2021-02-11, retrieved 2021-02-11^
  22. Argentina issues emergency approval to China's single-dose Cansino COVID-19 vaccine Reuters, 2021-06-11, retrieved 2021-06-11^
  23. ISP Approves Emergency Use And Importation Of Cansino Vaccine To Fight COVID-19 Institute of Public Health of Chile, retrieved 2021-04-08^
  24. Rashmi Ashok. UPDATE 2-China's CanSino Biologics COVID-19 vaccine receives emergency use approval in Hungary Reuters, 2021-03-22, retrieved 2021-03-22^
  25. Membrii NITAG au venit cu recomandări privind utilizarea vaccinurilor împotriva COVID-19 în Republica Moldova Ministerul Sănătății, Muncii și Protecţiei Sociale, 2021-03-03, retrieved 2021-05-21^
  26. China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year finance.yahoo.com, 27 February 2021, retrieved 2021-02-28^
  27. Daina Beth Solomon. China's CanSino says first vaccines packaged in Mexico will be ready in March Reuters, 2021-02-28, retrieved 2021-03-12^
  28. Pakistan develops homemade anti-Covid vaccine 'PakVac' The Express Tribune, 2021-05-24, retrieved 2021-05-25^